Analysts foresee more revenue UCB

Next Monday the Belgian company UCB will publish its past quarters results. Over the current book year the total revenue will be 4,7 billion euros (consensus estimates). This is slightly more than 2017's revenue of 4,63 billion euros.

Historical revenues and results UCB plus estimates 2018

The analysts expect for 2018 a net profit of 862 million euros. For this year the consensus of UCB's result per share is a profit of 4,61 euros. With this the price/earnings-ratio is 15,47.

Per share the analysts expect a dividend of 1,23 euros per share. Thus the dividend yield equals 1,73 percent. The average dividend yield of the pharmaceutical companies equals a limited 0,5 percent.

Newest target prices around 79 euros

The most recent recommendations for the pharmaceutical company are from KBC Securities, JP Morgan and HSBC.

UCB's market value equals around 13,42 billion . The UCB stock was the past 12 months quite unstable. Since last April the stock is 8 percent higher. This year the stock price moved between 60 and 81 euro. Since 2008 the stock price is almost 204 percent higher.

At 11.33 the stock trades 0,17 percent higher at 71,3 euros.

Historical stock prices UCB from 2007 till 2018

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.